Innovation: A New Desk for the Slow Idea
mRNA vaccines took decades. Lithium-ion took longer. Patient capital is the enabling mechanism — and it's structurally undersupplied.
In an era obsessed with disruption and rapid iteration, the value of the slow idea is often overlooked. True innovation frequently requires deep research, sustained investment, and a tolerance for failure that is antithetical to the demands of quarterly earnings cycles. A New Desk for the Slow Idea champions the importance of long-term thinking and foundational research.
The Case for Patient Capital
Patient capital — a form of long-term investment that aims to achieve both financial returns and social impact — is the enabling mechanism for slow ideas. Research demonstrates that patient capital enhances the performance of strategic emerging enterprises by providing long-term financial support and promoting technological innovation. Studies indicate that patient capital can significantly lead to key core technology breakthroughs, as it is highly compatible with long-term orientation and risk-sharing. The partial impact of patient capital is achieved through the intermediary of sustained research and development investment, which builds the knowledge base from which breakthroughs emerge.
The Ecosystems That Foster Slow Ideas
The ecosystems that foster slow ideas are diverse: academic institutions and government research labs provide the foundational research; corporate skunkworks and venture capital provide the translation from research to product; and patient institutional investors provide the capital to scale. The stories behind breakthrough technologies — from the decades-long development of mRNA vaccines to the multi-decade journey of lithium-ion batteries from laboratory curiosity to ubiquitous power source — underscore the need for a more patient and nuanced approach to innovation. In a world focused on the immediate, the slow idea may be the most powerful driver of long-term value creation.